Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced a £4.8 million (c. $6.5 million) extension to its Series C financing, in addition to the £14 million secured in March 2025, bringing the total in the round to £18.8 million (c. $25.4 million).
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
In this blog, Katherine Powers, Life Sciences Senior Analyst at RSM US, and Max Stanyard, Life Sciences Senior Analyst at RSM UK, highlight the investment uncertainty in the UK-US life sciences ecosystem.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
In this blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
Bidwells has completed the merger of Creative Places LLP into the firm, strengthening its Science & Technology capability and further enhancing its expertise in R&D and innovation-led real estate.
What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.
In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity.
The BioIndustry Association (BIA) has recognised the achievements of Dr Ruth McKernan CBE, neuroscientist, entrepreneur, investor and former Chair of the BIA Board, with the inaugural Chiswell Lifetime Achievement Award.
As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series.
UK biotech has demonstrated resilience in a challenging 2025 and enters 2026 with renewed confidence and broadening investor appetite, the BioIndustry Association’s (BIA) report UK biotech financing 2025 has found.
Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.
In 2025, the UK biotech sector continued to operate in a challenging financing environment, securing £1.9 billion in equity financing. Of this total, £1.8 billion was raised through venture capital, representing a 13.2% decrease year on year.
Infinitopes announced its second close of its seed financing round, securing an additional $15.4 million and bringing the total raised to $35.1 million.
As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.
